The NF-κB antagonist and p53-agonist activities of MDM2 inhibitors may have potential therapeutic effects by blocking the autoreactive T and B cell responses in systemic autoimmune disorders such as SLE. The gene discussed is NFKB1; the disease is systemic lupus erythematosus.